Key result
Prasugrel pretreatment increases 7-day non-CABG TIMI major bleeding risk by ~202% in NSTEMI patients.
Why the study?
Balancing the benefits of prasugrel antiplatelet therapy against bleeding risks in ACS patients requires identification of bleeding predictors.
What are the independent predictors of bleeding in patients with NSTEMI treated with prasugrel?
RCT (n=4,033)
Randomized
What are the independent predictors of bleeding in patients with NSTEMI treated with prasugrel?
Pretreatment with prasugrel, femoral access, female sex, placement of multiple stents, and older age are independent predictors of increased bleeding risk in NSTEMI patients.
Answers are grounded in this paper and cite their sources.
Supports avoiding prasugrel pretreatment in NSTEMI to curb bleeding; extends ACCOAST data on patient and procedural risk factors.
BACKGROUND: When considering antiplatelet therapy for acute coronary syndrome (ACS), it is essential to balance benefits (less thrombotic/ischaemic events) versus bleeding risks related to intense platelet inhibition via antagonism of P2Y12 receptors. This analysis aimed to identify predictors of bleeding events among A Comparison of Prasugrel at the Time of PCI or as Pretreatment at the Time of Diagnosis in Patients with NSTEACS (ACCOAST) study population. METHODS AND RESULTS: The ACCOAST study randomised 4033 patients with non-ST-segment elevation myocardial infarction (NSTEMI) to (A) a 30 mg prasugrel loading dose (LD) followed by coronary angiography with an additional 30 mg prasugrel at the time of percutaneous coronary intervention (PCI) or (B) a placebo LD followed by a 60 mg prasugrel at the time of PCI. Patients received standard of care, including use of aspirin. Independent predictors of Thrombolysis in Myocardial Infarction (TIMI) major bleeding not related to coronary artery bypass grafting (CABG) within 7 days were assessed using stepwise Cox proportional model for time to first occurrence of the event. Non-CABG-related TIMI major or minor bleeding was similarly analysed. Non-CABG-related TIMI major bleeding occurred in 36 (0.9%) patients, and TIMI major or minor bleeding occurred in 81 (2.0%) patients. Independent predictors for TIMI major bleeding alone were pretreatment with prasugrel LD (HR 3.02; 95% CI 1.42 to 6.43), femoral access (HR 2.45; 95% CI 1.11 to 5.38), female sex (HR 2.57; 95% CI 1.32 to 5.00), placement of >1 stent (HR 2.50; 95% CI 1.26 to 4.95) and age (HR 1.05; 95% CI 1.02 to 1.09). Pretreatment with prasugrel LD (HR 3.05; 95% CI 1.84 to 5.07), femoral access (HR 3.06; 95% CI 1.74 to 5.38), female sex (HR 2.62; 95% CI 1.67 to 4.12), performed PCI (HR 2.21; 95% CI 1.23 to 3.99), therapy with glycoprotein IIb/IIIa inhibitors (HR 1.88; 95% CI 1.06 to 3.33) and age (increased bleed per year of age HR 1.04; 95% CI 1.02 to 1.06) were independent predictors of TIMI major or minor bleeding through 7 days. CONCLUSIONS: Pretreatment, age, gender and procedural variables predicted bleeding risk in patients with NSTEMI. CLINICAL REGISTRATION NO: NCT01015287.
No takes yet. Share an insight, caveat, or question.
Widimský et al. (2015) conducted an RCT in Non-ST-segment elevation myocardial infarction (NSTEMI) (n=4,033). Prasugrel pretreatment vs. Placebo loading dose followed by 60 mg prasugrel at the time of PCI was evaluated on Non-CABG-related TIMI major bleeding within 7 days (HR 3.02, 95% CI 1.42 to 6.43). Pretreatment with a prasugrel loading dose increased the risk of non-CABG-related TIMI major bleeding within 7 days in patients with NSTEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: